March 2004 PBAC Outcomes - Deferrals
Table showing March 2004 PBAC Outcomes - Deferrals.
|
Drug and Form
|
Drug Use and Type
|
Listing requested by Sponsor
|
PBAC Recommendation
|
| Azithromycin tablet 500 mg
|
Antibiotic |
Unrestricted listing |
The PBAC deferred its decision to allow the sponsor an opportunity to comment on the
findings of the Expert Advisory Group on Antimicrobial Resistance.
|
| Sponsors comments: |
The sponsor has no comment. |
| Olanzapine tablets 2.5 mg, 5 mg, 7.5 mg and 10 mg, Zyprexa®, wafers 5 mg and 10 mg,
Zyprexa Zydis®
Eli Lilly Australia Pty Limited
|
Treatment for bipolar disorder |
Authority required listing |
The PBAC deferred its decision to allow the sponsor to clarify certain clinical issues
and to clarify its intention about the requested restriction.
|
| Sponsors comments: |
The sponsor disagrees with the decision but needs to clarify the decision with the
PBAC.
|
| Amino Acid formula without Phenylalanine, powder 400 g
Scientific Hospital Supplies
|
A food for inborn errors of metabolism |
Restricted benefit listing for phenylketonuria |
The PBAC deferred its decision to allow the sponsor to present further comparative
data.
|
| Sponsors comments: |
The sponsor will be responding to the PBAC's request. |
